Paper34099338
Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine.
Ulhaq ZS and 2 others. Indian J Med Microbiol, 2021. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine. Papers, record 34099338. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34099338
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| Vaccines | Major topic |
| Antibodies, Neutralizing | |
| Humans | |
| SARS-CoV-2 |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 33882219 | Vaccine Breakthrough Infections with SARS-CoV-2 Variants. | https://conductscience.org/library/papers/33882219 |
Source PubMed
References1
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|---|
| 1 | 33849893 | Covid-19: Chinese vaccines may need changes to improve efficacy, admits official. | BMJ | 2021 | https://conductscience.org/library/papers/33849893 |
Source PubMed
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37344265 | Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial. | Vaccine | 2023 | https://conductscience.org/library/papers/37344265 | PubMed |
| 35055707 | Symptomatic SARS-CoV-2 Infection with Ageusia after Two mRNA Vaccine Doses. | Int J Environ Res Public Health | 2022 | https://conductscience.org/library/papers/35055707 | PubMed |
| 34949742 | A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. | J Microbiol Biotechnol | 2021 | https://conductscience.org/library/papers/34949742 | PubMed |
| 34829969 | Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. | Biomedicines | 2021 | https://conductscience.org/library/papers/34829969 | PubMed |
| 34804022 | Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections. | Front Immunol | 2021 | https://conductscience.org/library/papers/34804022 | PubMed |
| 34682746 | SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature. | Int J Environ Res Public Health | 2021 | https://conductscience.org/library/papers/34682746 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34099338
GET https://conductscience.org/api/papers/v1/34099338/authors